Oncology

Bone

• There are currently no studies in this category.

Breast

• BMS CA163131 : A Randomized Phase 2 Study to Evaluate the Combinations of Ixabepilone plus Capecitabine or Docetaxel plus Capecitabine in the Treatment of Metastatic Breast Cancer (IXTEND) - Overview



• CINJ 040504: Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast Cancer - Overview



• ECOG PACCT-1 : Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial - Overview



• NCCTG N063D: A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination In Patients With HER2/Erbb2 Positive Primary Breast Cancer - Overview

Cervix

• GOG 0219 : A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine (IND #46525) and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis - Overview

Endometrial

• GOG 0209: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel In Patients With Stage III & IV or Recurrent Endometrial Cancer - Overview



• GOG 0210 : A Molecular Staging Study of Endometrial Carcinoma - Overview

Gastrointestinal

• CINJ 070501-5324: Phase II Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer - Overview



• Roche ML21567 : A Randomized Phase 2 Study of 7 on/7 off Capecitabine in Combination with Bevacizumab and Either Short-course Irinotecan or Short-course Oxaliplatin as First-Line Treatment for Patients with Metastatic Colorectal Cancer aka The “X-BIO” Study - Overview

Genitourinary

• SWOG S0421: III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer - Overview

Hematologic

• MGI DACO-016 : Randomized Phase 3 Trial of Decitabine Versus Patient’s Choice With Physician’s Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia - Overview

Lung

• Tragara TP2001-201: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients - Overview

Lymphatic

• There are currently no studies in this category.

Other

• Genentech AVF3991n : An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer - Overview



• GOG 0136: Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer - Overview

Ovary

• BioNumerik KTN32313R : A Phase 3 Study of Safety and Efficacy of Karenitecin versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Epithelial Ovarian Cancer - Overview



• Genentech AVF4095g: A Phase II, Multicenter, Randomized, Blinded Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma - Overview



• GOG 0212 : A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND #70177) Versus No Treatment Until Documented Relapse In Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane Chemotherapy - Overview



• GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or In Combination With Bevacizumab (NSC #704865, IND #7921) Followed By Bevacizumab and Secondary Cytoreductive Surgery In Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer - Overview



• GOG 0218 : A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC#704865, IND #7921) Followed By Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and All Stage IV, Epithelial Ovarian or Primary Peritoneal Cancer - Overview



• Marshall Edwards NV06-0039: Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy - Overview

Skin

• There are currently no studies in this category.

Vulva

• There are currently no studies in this category.